

Letter No.: GLHRL/35/2024-25

Date: October 28, 2024

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIPT CODE: 543520 ISIN: INE0J2K01014

Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,

Subject: Outcome of Meeting of Board of Directors held today i.e. Monday, October 28, 2024 for Consideration and approval of Unaudited Financial Results for the Half Year and Year ended on September 30, 2024.

Dear Sir/Madam.

In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that in the Board Meeting held today (i.e. Monday, October 28, 2024), the Board of Directors of the Company has considered and approved the Unaudited Financial Results for the Half Year ended September 30, 2024 along with the Limited Review Report.

The above matter has been duly approved by the Board of Directors at their meeting which commenced at 12:00 P.M. and concluded at 02:30 P.M.

In this connection, we are enclosing herewith Unaudited Financial Results for the Half year on September 30, 2024, along with the Limited Review Report.

The same will be made available on the Company's website www.globalhospital.co.in.

Kindly please take a note for the same and do the needful.

Thanking You,

Yours Faithfully,

For, Global Longlife Hospital and Research Limited

Dhruv Jani Managing Director DIN: 03154680

Encl: a/a



R. B. Gohil & Co. Chartered Accountants

LIMITED REVIEW REPORT ON UNAUDITED HALF YEARLY STANDALONE FINANCIAL RESULTS OF COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To the Board of Directors of Global Longlife Hospital and Research Limited

We have reviewed the accompanying statement of unaudited financial results of Global Longlife Hospital and Research Limited for the period ended 30th September, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, R B Gohil & Co. Chartered Accountants

FRN No. 119360W

Place: Jamnagar Date: 28/10/2024

CA Raghubha B. Gohil

Partner

M.No. 104997

UDIN: 24104997BKBIYK7928



GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

REGD OFFICE: GLOBAL HOSPITAL, OPP. AUDA GARDEN, NR. WATER TANK, BODAKDEV, AHMEDABAD - 380054

UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON 30.09.2024

-		(Rs, in Lakhs except per share data) Half Year Ended Year Ended					
Sr. No.	Particulars			30,09,2023 31.03.2024		31.03.2023	
		30.09.2024	31.03.2024	Unaudited	Audited	Audited	
		Unaudited	Audited	Unaudited	Audited	Audited	
	Revenue from Operations	57.73	118.45	1,233.00	1,351.45	2,350.17	
_	Other Income	568.97	4.23	2.10	6.33	23.87	
1	Total Income	626.70	122.69	1,235.09	1,357.78	2,374.04	
2	Expenses	626,70	122.09	1,235.09	1,337.76	2,0 / 110 1	
_	Direct Expenses	116.01	156.87	567.58	724.45	915.02	
	Purchase of Stock-in-Trade	110.01	0.61	83.59	84.20	426.44	
	Changes in inventories of finished goods and stock in trade	43.72	85.71	(47.88)	37.83	6.73	
	Employee benefits expenses	43.08	118.40	215.29	333.69	363.02	
	Finance Costs	27.56	36.32	40.51	76.83	40.05	
	Depreciation and amortisation expenses	48.38	63.52	61.49	125.01	116.65	
	Other Expenses	236.67	58.80	143.56	202.36	235.35	
	Total Expenses	515.42	520.23	1,064.14	1,584.37	2,103.26	
3	Profit/(Loss) before exceptional and extrordinary items and tax (1 - 2)	111.28	(397.55)	170.96	(226.59)	270.78	
	Exceptional Items	111.20	(371,33)	-	(220,07)		
	Profit/(Loss) before extraordinary item and tax (3 - 4)	111.28	(397.55)	170.96	(226.59)	270.78	
6	Extraordinary Items	111.20	(377,33)	170.50	(220:05)	-	
7	Profit/(Loss) before tax (5 - 6)	111.28	(397.55)	170,96	(226.59)	270,78	
8	Tax Expense	111.20	(377.33)	170,70	(220(23))		
_	a) Current tax	_	(28.54)	28.54		45.20	
	b) Deferred tax	(12.58)	(47.26)	39.48	(7.78)	42.73	
	c) Excess/(Short) Provision Of Earlier Years	(12.38)	(47.20)	-	(7.70)	0.10	
0	Net Profit/(Loss) from continuing activities after tax (7 - 8)	123.86	(321.75)	102.94	(218.81)	182,75	
10	Net Profit/(Loss) from discontinued operations before tax	123.00	(321.73)	102.74	(210.01)	10211	
	Tax Expense of discontinued operations	-	-			_	
12		-	-		-		
_	Net Profit/(Loss) for the period after tax (9 + 12)	123.86	(321.75)	102.94	(218.81)	182.7	
	Other Comprehensive Income, net of tax (OCI)	123.00	(321.73)	102.54	(210.01)	102.7	
14	a) Items that will not be reclassified to profit or loss			_	-	-	
-	b) Income tax relating to items that will not be reclassified to profit or loss	-	-	_	· -		
-	Total		<u> </u>	-	-	-	
1.5		123.86	(221.75)	102,94	(218.81)	182,7	
	Total Comprehensive Income for the period (13+14) Details of Equity Share Capital	123.80	(321.75)	102,94	(210.01)	102.7	
		1.050.00	1.050.00	1,050.00	1,050.00	1.050.0	
	Paid-up Equity Share Capital Face Value of Equity Share Capital	1,050.00	1,050.00	1,030.00		1,050.0	
	Reserves excluding revaluation reserves	10.00	10.00	10.00	1,543.14		
_			-		1,343.14	3,378.5	
8	Basic earning (loss) per share from continuing and discountinued operation	1.18	(3.06)	0.98	(2.08) 1.	
	Diluted earning (loss) per share from continuing and discountinued operation	1.18	(3.06)	0.98	(2.08	1.	
	Debt Equity Ratio	-	0.49	0.17	0.49	0.	
	Debt Service Coverage Ratio	0.43	(11.08)				
	Interest Service Coverage Ratio	28.04	(24.38)				

For, Global Longlife Hospital and Research Limited

Dhruv Jani Managing Director DIN: 03154680 Date: 28-10-2024 Place: Ahmedabad

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

7) *Reed office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India Tel No.: (079) 29708041; Email: investor@globalhospital.co.in; Website: www.globalhospital.co.in;



GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED CIN: L85110GJ2012PLC068700 REGD OFFICE: GLOBAL HOSPITAL, OPP. AUDA GARDEN, NR. WATER TANK, BODAKDEV,

			(Rs. In Lakhs)
	Particulars	As At 30.09.2024	As At 31.03.2024
		Unaudited	Audited
	Equity and liabilities		
1	Shareholders' funds		
	Share capital	1,050.00	1,050.00
	Reserves and surplus	1,667.00	1,543.14
	Money received against share warrants	1,007.00	1,343.14
	Total shareholders' funds	2,717.00	2,593.14
2	Shara application		
3	Share application money pending allotment Deferred government grants	-	-
4	Minority interest	-	-
4	ivinionty interest	-	-
5	Non-Current Liabilities		
	Long-term borrowings		340.97
	Deferred tax liabilities (net)	_	340.97
	Other long-term liabilities		0.89
	Long-term provisions	4.80	4.81
	Total Non-Current Liabilities		346.67
6	Current Liablities		
	Short-term borrowings		932.7
	Trade Payables		
	(A) Total outstanding dues of micro enterprises and small enterprises.		
	(B) Total outstanding dues of creditors other than		62.9
	micro enterprises and small enterprises.	1.65	100
	Other current liabilities	11.21	192.9
	Short-term provisions	1.94	1.
	Total current liabilitie		1,233.
	Total equity and liabilitie		4,173.

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

Regd. Office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India Tel No.: (079) 29708041; Email: investor@globalhospital.co.in; Website: www.globalhospital.co.in;



	Assets		
1	Non-current assets		
(i)	Fixed assets		
	Tangible assets		1,725.70
	Producing properties		
	Intangible assets		1.30
	Preproducing properties		
	Tangible assets capital work-in-progress		
	Intangible assets under development or work-in-		-
	Total fixed assets	-	1,727.00
(ii)	Non-current investments	1,866.50	3.00
(iii)	Deferred tax assets (net)	234.83	222,25
(iv)	Long-term loans and advances	-	-
(v)	Other non-current assets	188.84	1,828.52
(*/	Total non-current assets	2,290.17	2,053.77
2	Current assets		42.72
	Inventories		43.72
	Trade receivables	129.65	194.60
	Cash and cash equivalents	174.82	38.54
	Short-term loans and advances	131.81	108.96
	Other current assets	10.15	6.45
	Total current assets	446.42	392.27
	Total assets	2,736.59	4,173.04

For, Global Longlife Hospital and Research Limited

BODAKDEV

Dhruv Jani

Managing Director

DIN: 03154680

Date: 28-10-2024 Place: Ahmedabad

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

Regd. Office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India Tel No.: (079) 29708041; Email: investor@globalhospital.co.in; Website: www.globalhospital.co.in;



GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED CIN: L85110GJ2012PLC068700 REGD OFFICE: GLOBAL HOSPITAL, OPP. AUDA GARDEN, NR. WATER TANK, BODAKDEV, AHMEDABAD

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30.09.2024

	20.00	T	Amount in Lakhs	
Particulars	30-09-2024 Unaudited	30-09-2023 Unaudited	31-03-2024 Audited	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit before taxation and extraordinery items				
Adjustment for :-	111.28	170.96	(226.5	
Depreciation and Amortization				
Non-cash items	48.38	61 49	125.0	
Loss on sale of asset	-		57.58	
Change in Reserve & Surplus	-	5.83	5.83	
Finance Costs			(3,617.02	
	27.56	40.51	76.83	
Operating Profit berfore working capital changes	187.21	278.79	(3,578.30	
Change in working Capital ·			· · · · · · · · · · · · · · · · · · ·	
Adjustment for Decrease (Increase) in operating assets				
Inventories (Increase) in operating assets				
Trade receivables	43.72	(47.88)	37.83	
Other Current Assets & Loans Advances	64.95	(289.93)	775.09	
Other Non current Asset	(26.55)	26.42	2,157.84	
Adjustment for (December 1)	1,639.68	20.42	2,137.84	
Adjustment for (Decrease) Increase in opearting liabilities Trade payables	7.2.2.0			
Other current liabilities	(254.23)	(10.50)		
Other Parallel Habilities	(31.49)	(40 56)	124.79	
Other Provision	(0.90)	3 41	(5.20	
Cash Generated from Operations	(0.90)	0.52	(3.49	
Direct tax Paid				
Dividends received	(0.45)	(61 83)	9.72	
Interest received	(0.45)	(1.50)	(1.50	
	(4.12)	(0.27)	(4.44	
Net cash from Operating Activities				
	1,617.82	(132.83)	(507.22	
B. NET CASH FLOW FROM INVESTMENT ACTIVITIES			(=0,12	
1. di chidac di l'ixedi Assets				
Purchase of Property, Plant and Equipment				
Proceeds from Sale of Equity Instruments		(78.11)	(104.00	
Proceeds from sales of property, plant and equipment		(78.11)	(104.89	
Loans and Advances given	1,678.62	5.02	7.00	
Dividends received	-,0.02	5.83	2.15	
Interest received	0.45	(3.28)		
Proceed C	4.12	1.50	1.50	
Proceeds from maturity of term deposits	4.12	0.62	4.44	
Investment in Securities	(1.000.00)		8.04	
Investment in Term Deposits	(1,863.50)			
Proceeds from sale of fixed assets		(2.54)	-	
Net Cash from Investment Activities				
	(180.31)	(75.97)	(01.7)	
CASH FLOWS FROM FINANCING ACTIVITIES		(1007)	(81.75	
Repayment of Long Term Romand				
repayment of Long Term Romowings	(340.97)	(225.24)		
Proceeds from Short Term Borrowings	(340.97)	(225.34)	(23.20	
Proceeds from Short Term Borrowings Repayment of Short Term Borrowings	· ·	(225.34) 426.35	(23.26	
Repayment of Long Term Borrowings Repayment of Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares	(340.97)			
Repayment of Long Term Borrowings Proceeds from Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings	· ·			
Repayment of Long Term Borrowings Proceeds from Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings	· ·			
Repayment of Long Term Borrowings Proceeds from Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings Repayments of borrowings Dividends paid	· ·			
Repayment of Long Term Borrowings Repayment of Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings Dividends paid Interest paid	· ·			
Repayment of Long Term Borrowings Repayment of Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings Dividends paid Interest paid	· ·	426.35	367.4	
Proceeds from Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings Repayments of borrowings Dividends paid Interest paid Net Cash from financial activities	(932.71) (932.71) (27.56) (1.301.24)	426.35	(76.8)	
Proceeds from Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings Repayments of borrowings Dividends paid Interest paid Net Cash from financial activities	(932.71) (932.71) (27.56) (1.301.24)	426.35		
Repayment of Long Term Borrowings Repayment of Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings Dividends paid Dividends paid Net Cash from financial activities T INCREASE /(-) DECREASE IN CASH AND CASH EQUITATIONS	(932.71) (932.71) (27.56) (1,301.24)	(40 51) 160.49	(76.8: 267.3:	
Repayment of Long Term Borrowings Repayment of Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings Dividends paid Interest paid Net Cash from financial activities T INCREASE /(-) DECREASE IN CASH AND CASH EQUIP ENING BALANCE IN CASH AND CASH EQUIP	(932.71) (932.71) (27.56) (1,301.24) (136.27)	426.35	(76.8)	
Proceeds from Short Term Borrowings Repayment of Short Term Borrowings Proceeds from issuing shares Proceeds from borrowings Repayments of borrowings Repayments of borrowings Dividends paid Interest paid Net Cash from financial activities	(932.71) (932.71) (27.56) (1,301.24) (136.27)	(40 51) 160.49	(76.8: 267.3:	

For, Global Longlife Hospital and Research Limited

Dhruv Jani Managing Director DIN: 03154680

Date: 28-10-2024 Place: Ahmedabad

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED
CIN: L85110GJ2012PLC068700

CIN: L85110GJ2012PLC.08700

Regd. Office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad - 380 059, Gujarat, India
Tel No.: (079) 29708041; Email: investor@globalhospital.co.in; Website: www.globalhospital.co.in;



- 1) The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its Meeting held on October 28, 2024.
- 2) The statutory auditor has carried out a limited review of this financial results & expressed an unmodified review opinion.
- 3) The company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under AS - 17 Segment Reporting.
- 4) The accompanying financial results include the results for the half year ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the first half year ended as on 30th September, 2023 of the previous financial year.
- 5) Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.
- 6) As the company is listed on SME Platform of BSE, it has been exempted from the applicability of IND-AS as per the proviso to rule 4 of companies (Indian Accounting Standards) Rules, 2015.
- 7) The Financial results have been prepared in accordance with the accounting standard as notified under section 133 of the Companies Act 2013 (Act), read with the relevant rules made thereunder and other accounting principles generally accepted in India.
- 8) The results for the half year ended 30th September, 2024 are available on the BSE Limited website (URL: www.bseindia.com) and also on the company's website (URL: www.globalhospital.co.in)
- 9) As the company do not have any Holding/Subsidiary/Joint Venture/Associate concern, no reporting has been made in this regards.



GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED

CIN: L85110GJ2012PLC068700

Regd. Office: 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad – 380 059, Gujarat, India Tel No.: (079) 29708041; Email: investor@globalhospital.co.in; Website: www.globalhospital.co.in;